Posted by Clinical Lab Products | Jun 25, 2010 | Miscellaneous |
Health Diagnostic Laboratory Inc announced its new capability to run the CYP2C19 genetic test. HDL Inc, headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.
Read MorePosted by Clinical Lab Products | Jun 18, 2010 | Miscellaneous, Osteoporosis |
QIAGEN has announced that it has entered into an agreement with the Dutch molecular diagnostic component supplier Genome Diagnostics which covers the development and commercialization of 6 new tests until 2011.
Read MorePosted by Clinical Lab Products | Jun 18, 2010 | Miscellaneous |
The FDA has announced plans to hold a public meeting on July 19 to 20 to discuss how the agency will oversee laboratory-developed tests (LDTs).
Read MorePosted by Clinical Lab Products | Jun 14, 2010 | Cancer, Miscellaneous |
Response Genetics Inc, a company focused on the development and commercialization of molecular diagnostic tests for cancer, announced the addition of Michael B. McNulty as the Companys chief operating officer.
Read MorePosted by Clinical Lab Products | Jun 11, 2010 | Cancer, Miscellaneous |
Clarient Inc announces a new contractual agreement with Generation Health Inc (GH) making Clarient a preferred genetic testing lab for GH.
Read More